BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis
Clinicians have long sought to characterize biological markers of neoplasia as objective
indicators of tumor presence, pathogenicity, and prognosis. Armed with data that correlate …
indicators of tumor presence, pathogenicity, and prognosis. Armed with data that correlate …
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
M Xing, WH Westra, RP Tufano, Y Cohen… - The Journal of …, 2005 - academic.oup.com
Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve
risk stratification of this cancer. Objective: The objective of the study was to investigate the …
risk stratification of this cancer. Objective: The objective of the study was to investigate the …
BRAF mutation is not predictive of long‐term outcome in papillary thyroid carcinoma
LE Henke, JD Pfeifer, C Ma, SM Perkins… - Cancer …, 2015 - Wiley Online Library
The BRAF mutation occurs commonly in papillary thyroid carcinoma (PTC). Previous
investigations of its utility to predict recurrence‐free survival (RFS) and disease‐specific …
investigations of its utility to predict recurrence‐free survival (RFS) and disease‐specific …
[HTML][HTML] Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis
C Liu, T Chen, Z Liu - World journal of surgical oncology, 2016 - Springer
Background The objective of this study is to perform a meta-analysis to evaluate the
associations between the BRAF V600E mutation status and aggressive clinicopathological …
associations between the BRAF V600E mutation status and aggressive clinicopathological …
Association Between BRAF V600E Mutation and Recurrence of Papillary Thyroid Cancer
M Xing, AS Alzahrani, KA Carson, YK Shong… - Journal of clinical …, 2015 - ascopubs.org
Purpose To investigate the prognostic value of BRAF V600E mutation for the recurrence of
papillary thyroid cancer (PTC). Patients and Methods This was a retrospective multicenter …
papillary thyroid cancer (PTC). Patients and Methods This was a retrospective multicenter …
BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications
M Xing - Endocrine reviews, 2007 - academic.oup.com
In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …
received enthusiastic investigation, and significant progress has been made toward …
BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications
KT Tang, CH Lee - Journal of the chinese medical association, 2010 - journals.lww.com
Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–
90% of all thyroid cancers. Genetic alternations involving the mitogen-activated protein …
90% of all thyroid cancers. Genetic alternations involving the mitogen-activated protein …
Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: A meta‐analysis
JH Lee, ES Lee, YS Kim - Cancer, 2007 - Wiley Online Library
BACKGROUND. Numerous studies have investigated the clinical significance of BRAF
mutation in papillary thyroid carcinoma (PTC). However, there have been conflicting data on …
mutation in papillary thyroid carcinoma (PTC). However, there have been conflicting data on …
BRAF V600E mutation and Its Association with Clinicopathological Features of Papillary Thyroid Cancer: A Meta-Analysis
C Li, KC Lee, EB Schneider… - The Journal of Clinical …, 2012 - academic.oup.com
Background: There is conflicting literature regarding the association of the BRAF V600E
mutation and aggressive clinicopathological features of papillary thyroid cancer (PTC) …
mutation and aggressive clinicopathological features of papillary thyroid cancer (PTC) …
Prognostic utility of BRAF mutation in papillary thyroid cancer
M Xing - Molecular and cellular endocrinology, 2010 - Elsevier
Papillary thyroid cancer (PTC) is a common endocrine malignancy that frequently harbors
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
the oncogenic T1799A BRAF mutation. As a novel prognostic molecular marker, this …
相关搜索
- braf mutation thyroid cancer
- meta analysis thyroid cancer
- braf mutation clinical implications
- braf mutation meta analysis
- meta analysis papillary carcinomas
- braf mutation prognostic utility
- prognostic utility thyroid cancer
- meta analysis prognostic factors
- braf v600e thyroid carcinoma
- braf mutation molecular bases
- molecular bases thyroid cancer
- clinicopathological features thyroid cancer
- clinical implications thyroid cancer
- meta analysis clinicopathologic significance
- meta analysis poor outcomes
- braf mutation thyroid carcinoma